Close Menu

non-small cell lung cancer

This article has been updated to correct the name of the Phase I extension trial to Study 1001. Originally published June 3.

Using a pharmacogenetic strategy to home in on a molecularly defined non-small cell lung cancer patient population, researchers have shown in a clinical trial that the investigational EGFR inhibitor afatinib significantly prolongs survival in patients with EGFR-mutated tumors.

Eli Lilly said last week that it received a complete response letter from the US Food and Drug Administration declining its application to market Erbitux as a first-line treatment for non-small cell lung cancer.

Biodesix last week presented results from a combined analysis of two Phase II trials using its Veristrat lung cancer companion diagnostic.

By Adam Bonislawski
Somalogic last week published in PLoS One a study offering the first data on use of its aptamer-based Somascan platform in tissue samples.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.